Low sensitivity to glucocorticoid inhibition of in vitro Th17-related cytokine production in multiple sclerosis patients is related to elevated plasma lipopolysaccharide levels

Clinical Immunology

Volumn 148, Issue 2, 2013, Pages 209-218

  Teixeira, Bruna ^a   Bittencourt, Vera Carolina B ^a   Ferreira, Thais B ^a   Kasahara, Taissa M ^a   Barros, Priscila O ^a   Alvarenga, Regina ^a   Hygino, Joana ^a   Andrade, Regis M ^a   Andrade, Arnaldo F ^b   Bento, Cleonice A M ^a  

^a FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

CD8+ T cells; Cytokines; ; IL 10; ; Lipopolysaccharide; ; Multiple sclerosis; ; Th17;

Indexed keywords

GLUCOCORTICOID; HYDROCORTISONE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; LIPOPOLYSACCHARIDE;

ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PHENOTYPE; PRIORITY JOURNAL; RELAPSE; REMISSION; T LYMPHOCYTE; TH17 CELL;

CD8(+) T CELLS; CYTOKINES;; IL-10;; LIPOPOLYSACCHARIDE;; MULTIPLE SCLEROSIS;; TH17;;

ADULT; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS; TH17 CELLS; YOUNG ADULT;

EID: 84879363514     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.05.012     Document Type: Article

References (59)

1. Adams R.D., Victor M. Multiple sclerosis and allied demyelinative diseases. Principles of Neurology 1989, 4:755-774.
2. Schumacher G.A., Beebe G., Kibler B.G., Kurland L.T., Kurtzke J.F., McDowell F., Nagler B., Sibley W.A., Tourtellotte W.W., Willmon T.L. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on evaluation of experimental trials of therapy in multiple sclerosis. Ann. N. Y. Acad. Sci. 1965, 122:552-568.
3. Lovett-Racke A.E., Yang Y., Racke M.K. Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis?. Biochem. Biophys. Acta 1812, 2011:246-251.
4. Langrish C.L., Chen Y., Blumenschein M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
5. Komiyama Y., Nakae S., Matsuki T., Nambu A., Kakuta H.S., Suko K., Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:566-573.
6. Becher B., Durell B.G., Noelle R.J. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J. Clin. Invest. 2002, 110:493-497.
7. Okuda Y., Sakoda S., Bernard C.C., Fujimura H., Saeki Y., Kishimoto T., Yanagihara T. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. 1998, 10:703-708.
8. Brucklacher-Waldert V., Sturner K., Kolster M., Wollhausen J., Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009, 132:3329-3341.
9. Matusevicius D., Kivisakk P., Be H., Kostulas N., Ozenci V., Fredrikson S., Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 1999, 5:101-104.
10. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8:500-508.
11. Kebir H., Ifergan I., Alvarez J.I., Bernard M., Poirier J., Arbour N., Duquette P., Prat A. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann. Neurol. 2009, 66:390-402.
12. Skurkovich S., Boiko A., Beliava I., Buglak A., Alekseeva T., Smirnova N., Kulakova O., Tchechonin V., Gurova O., Deomina T., Favorova O.O., Skurkovic B., Gusev E. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Mult. Scler. 2001, 7:277-284.
13. Bjartmar C., Wujek J.R., Trapp B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 2003, 206:165-171.
14. Maynard C.L., Harrington L.E., Janowski K.M., Oliver J.R., Zindl C.L., Rudensky A.Y. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat. Immunol. 2007, 8:931-941.
15. Shevach E.M. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
16. Belkaid Y. Regulatory T, cells and infection: a dangerous necessity. Nat. Rev. Immunol. 2007, 7:875-888.
17. Li M.O., Flavell R.A. Contextual regulation of inflammation: a duet by transforming growth factor-b and interleukin-10. Immunity 2008, 8:468-476.
18. McGeachy M.J., Stephens L.A., Anderton S.M. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory T cells within the central nervous system. J. Immunol. 2005, 175:3025-3032.
19. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199:971-979.
20. Venken K., Hellings N., Thewissen M., Somers V., Hensen K., Rummens J.-L., Medaer R., Hupperts R., Stinissen P. Compromised CD4+ CD25 high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 2007, 123:79-89.
21. Michel L., Berthelot L., Pettré S., Wiertlewski S., Lefrère F., Braudeau C., Brouard S., Soulillou J.P., Laplaud D.A. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL receptor α-chain are excluded from the analysis. J. Clin. Invest. 2008, 118:3411-3419.
22. Hensen J.-L., Venken P., Hellings N., Broekmans T., Hensen K., Rummens J.L., Stinissen P. Recovery of memory Treg Homeostasis during disturbed in multiple sclerosis patients: T cell (Treg) development and function are natural naive CD4+CD25+CD127 low regulatory. J. Immunol. 2008, 180:6411-6420.
23. Ma A., Xiong Z., Hu Y., Qi S., Song L., Dun H., Zhang L., Lou D., Yang P., Zhao Z., Wang X., Zhang D., Daloze P., Chen H. Dysfunction of IL-10-producing type 1 regulatory T cells and CD4+CD25+ regulatory T cells in a mimic model of human multiple sclerosis in Cynomolgus monkeys. Int. Immunopharmacol. 2009, 9:599-608.
24. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.-P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50(1):121-127.
25. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983, 33:1444-1452.
26. Hollifield R.D., Harbige L.S., Pham-Dinh D., Sharief M.K. Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity 2003, 36(3):133-141.
27. Głabiński A., Mirecka M., Pokoca L. Tumor necrosis factor alpha but not lymphotoxin is overproduced by blood mononuclear cells in multiple sclerosis. Acta Neurol. Scand. 1995, 91(4):276-279.
28. Luger D., Silver P.B., Tang J., Cua D., Chen Z., Iwakura Y., Bowman E.P., Sgambellone N.M., Chan C.C., Caspi R.R. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 2008, 205:799-810.
29. Merril J.E., Mohlstrom C., Uittenbogaart C., Kermaniarab V., Ellison G.W., Myers L.W. Response to and production of interleukin 2 by peripheral blood and cerebrospinal fluid lymphocytes of patients with multiple sclerosis. J. Immunol. 1984, 133:1931-1937.
30. Killestein J., Hintzen R.Q., Uitdehaag PA Baars B.M., Roos M.T., van Lier R.A., et al. Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta. J. Neuroimmunol. 2002, 133:217-224.
31. Costa V.S., Mattana T.C., da Silva M.E. Unregulated IL-23/IL-17 immune response in autoimmune diseases. Diabetes Res. Clin. Pract. 2010, 88:222-226.
32. Morrison P.J., Ballantyne M.C. Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity. Immunology 2011, 133:397-408.
33. Wang H.H., Dai Y.Q., Qiu W., Lu Z.Q., Peng F.H., Wang Y.G., et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J. Clin. Neurosci. 2011, 18:1313-1317.
34. Kroenke M.A., Carlson T.J., Andjelkovic A.V., Segal B.M. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 2008, 205:1535-1541.
35. Gyulveszi G., Haak S., Becher B. IL-23-driven encephalo-tropism and Th17 polarization during CNS-inflammation in vivo. Eur. J. Immunol. 2009, 39:1864-1869.
36. Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., Parente E., Fili L., Ferri S., Frosali F., Giudici F., Romagnani P., Parronchi P., Tonell F., Maggi E., Romagnani S. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007, 204:1849-1861.
37. Romagnani S. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007, 204:1849-1861.
38. Ashwell J.D., Lu F.W., Vacchio M.S. Glucocorticoids in T cell development and function. Annu. Rev. Immunol. 2000, 18:309.
39. van Winsen L.M., Muris D.F., Polman C.H., Dijkstra C.D., van den Berg T.K., Uitdehaag B.M. Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis. J. Clin. Endocrinol. Metab. 2005, 90(2):734-740.
40. De Bosscher K., Vanden Berghe W., Vermeulen L., Plaisance S., Boon E., Haegeman G. Glucocorticoids repress NF-kappaB driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc. Natl. Acad. Sci. 2000, 97(8):3919-3924.
41. Schmitz M.L., Bacher S., Dienz O. NF-kappaB activation pathways induced by T cell costimulation. FASEB J. Dec 2003, 17(15):2187-2193.
42. Gold S.M., Sasidhar M.V., Lagishetty V., Spence R.D., Umeda E., Ziehn M.O., Krieger T., Schulz K.H., Heesen C., Hewison M., Voskuhl R.R. Dynamic development of glucocorticoid resistance during autoimmune neuroinflammation. J. Clin. Endocrinol. Metab. 2012, 97(8):E1402-E1410.
43. De Kloet C.S., Vermetten E., Bikker A., Meulman E., Geuze E., Kavelaars A., Westenberg H.G., Heijnen C.J. Leukocyte glucocorticoid receptor expression and immunoregulation in veterans with and without post-traumatic stress disorder. Mol. Psychiatry 2007, 12:443-453.
44. Gotovac K., Sabioncello A., Rabatic S., Berki T., Dejaris D. Flow cytometric determination of glucocorticoid receptor (GCR) expression in lymphocyte subpopulations: lower quantity of GCR in individuals with post-traumatic stress disorder (PTSD). Clin. Exp. Immunol. 2003, 131:335-339.
45. Matysiak M., Makosa B., Walczak A., Selmaj K. Patients with multiple sclerosis resisted to glucocorticoid therapy: abnormal expression of heat-shock protein 90 in glucocorticoid receptor complex. Mult. Scler. 2008, 14(7):919-926.
46. Lien E., Ingalls R.R. Toll-like receptors. Crit. Care Med. 2002, 30(1 Suppl.):S1-S11.
47. Schrijver I.A., van Meurs M., Melief M.J., Wim Ang C., Buljevac D., Ravid MP Hazenberg R., Laman J.D. Bacterial peptidoglycan and immune reactivity in the central nervous system in multiple sclerosis. Brain 2001, 124:1544-1554.
48. Bsibs M., Ravid R., Gveric D., van Noort J.M. Broad expression of Toll-like receptor ors in the human central nervous system. J. Neuropathol. Exp. Neurol. 2002, 61:1013-1021.
49. Hansen B.S., Hussain R.Z., Lovett-Racke A.E., Thomas J.A., Racke M.K. Multiple Toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity. J. Neuroimmunol. 2006, 172:94-103.
50. Babu S., Blauvelt C.P., Kumaraswami V., Nutman T.B. Cutting edge: diminished T cell TLR expression and function modulates the immune response in human filarial infection. J. Immunol. 2006, 176:3885-3889.
51. Gururajan M., Jacob J., Pulendran B. Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS One 2007, 2:e863.
52. Pietschmann K., Beetz S., Welte S., Martens I., Gruen J., Oberg H.H., Wesch D., Kabelitz D. Toll-like receptor expression and function in subsets of human gammadelta T lymphocytes. Scand. J. Immunol. 2009, 70:245-255.
53. Zarember K.A., Godowski P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products and cytokines. J. Immunol. 2002, 168:554-561.
54. Jin B., Sun T., Yu X.H., Yang Y.X., Yeo A.E. The effects of TLR activation on T-cell development and differentiation. Clin. Dev. Immunol. 2012, 2012:1-32.
55. Mansson A., Adner M., Cardell L.O. Toll-like receptors in cellular subsets of human tonsil T cells: altered expression during recurrent tonsillitis. Respir. Res. 2006, 7:36-45.
56. Wong C.K., Wong P.T., Tam L.S., Li E.K., Chen D.P., Lam C.W. Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2010, 159:11-22.
57. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., Endres S., Hartmann G. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 2002, 168:4531-4537.
58. Beiske A.G., Svensson E., Sandanger I., Czujko B., Pedersen E.D., Aarseth J.H., Myhr K.M. Depression and anxiety amongst multiple sclerosis patients. Eur. J. Neurol. 2008, 15(3):239-245.
59. Chang L. The role of stress on physiological responses and clinical symptoms in irritable bowel syndrome. Curr. Mol. Med. 2008, 8(4):299-312.